



Published in final edited form as:

*J Acquir Immune Defic Syndr.* 2021 March 01; 86(3): 339–343. doi:10.1097/QAI.0000000000002556.

## Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era

SA Ruderman<sup>1</sup>, HM Crane<sup>1</sup>, RM Nance<sup>1</sup>, BM Whitney<sup>1</sup>, BN Harding<sup>1</sup>, KH Mayer<sup>2</sup>, RD Moore<sup>3</sup>, JJ Eron<sup>4</sup>, E Geng<sup>5</sup>, WC Mathews<sup>6</sup>, AL Willig<sup>7</sup>, GA Burkholder<sup>7</sup>, S Lindström<sup>1</sup>, BR Wood<sup>1</sup>, AC Collier<sup>1</sup>, V Vannappagari<sup>8</sup>, C Henegar<sup>8</sup>, J Van Wyk<sup>9</sup>, L Curtis<sup>10</sup>, MS Saag<sup>7</sup>, MM Kitahata<sup>1</sup>, JAC Delaney<sup>1,11</sup>

<sup>1</sup>University of Washington, Seattle, WA, USA;

<sup>2</sup>Harvard Medical School, Fenway Institute, Boston, MA, USA;

<sup>3</sup>Johns Hopkins, Baltimore, MD, USA;

<sup>4</sup>University of North Carolina, Chapel Hill, NC, USA;

<sup>5</sup>University of California San Francisco, San Francisco, CA, USA;

<sup>6</sup>University of California San Diego, San Diego, CA, USA;

<sup>7</sup>University of Alabama at Birmingham, Birmingham, AL, USA;

<sup>8</sup>ViiV Healthcare, RTP, NC, USA;

<sup>9</sup>ViiV Healthcare, Brentford, UK;

<sup>10</sup>GlaxoSmithKline, Uxbridge, UK;

<sup>11</sup>University of Manitoba, Winnipeg, Canada

### Abstract

**Objectives**—Evaluate differences in weight change by regimen among people living with HIV (PLWH) initiating antiretroviral therapy (ART) in the current era.

**Methods**—Between 2012–2019, 3232 ART-naïve PLWH initiated 3-drug ART regimens in eight Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites. We estimated weight change by regimen for 11 regimens in the immediate (first 6-months) and extended (all follow-up on initial regimen) periods using linear mixed models adjusted for time on regimen, interaction between time and regimen, age, sex, race/ethnicity, hepatitis B/C coinfection, nadir CD4, smoking, diabetes, antipsychotic medication, and site. We included more recently

---

**Corresponding Author:** Stephanie A. Ruderman (ruderman@uw.edu).

**Data Presented in part at:** 17<sup>th</sup> European AIDS Conference 2019, November 6–9, 2019, Basel, Switzerland; AIDS 2020, July 6–10, 2020, presented virtually

**Conflicts of interest:** All of the authors have viewed this final draft and have each contributed significantly to its design and content. The following have served as a consultant, advisor or received research funding: MSS from Gilead, Merck, Proteus, and ViiV Healthcare; JJE from ViiV Healthcare, Janssen, Gilead and Merck; HMC from ViiV Healthcare. The following have no conflicts of interest: SAR, JACD, WCM, BMW, RMN, BNH, KHM, ALW, GAB, SL, BRW, ACC, MMK, RDM, and EG. The following are employees of ViiV Healthcare: VV, CH, JV, and LK. Final content decisions were made by SAR, JACD, and HMC. ViiV Healthcare manufactures dolutegravir and manufacturers of other integrase inhibitors have funded JJE and MSS.

approved regimens (e.g. with tenofovir alafenamide fumarate (TAF)) only in the immediate period analyses to ensure comparable follow-up time.

**Results**—Mean follow-up was 1.9 years on initial ART regimen. In comparison to efavirenz/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), initiating bictegravir/TAF/FTC (3.9kg (95% CI:2.2–5.5)) and dolutegravir/TAF/FTC (4.4kg (95% CI:2.1–6.6)) were associated with the greatest weight gain in the immediate period, followed by darunavir/TDF/FTC (3.7kg (95% CI:2.1–5.2)) and dolutegravir/TDF/FTC (2.6kg (95% CI:1.3–3.9)). In the extended period, compared with efavirenz/TDF/FTC, initiating darunavir/TDF/FTC was associated with a 1.0kg (95% CI:0.5–1.5) per 6-months greater weight gain, while dolutegravir/abacavir/FTC was associated with a 0.6kg (95% CI:0.3–0.9) and dolutegravir/TDF/FTC was associated with a 0.6kg (95% CI:0.1–1.1) per 6-months greater gain. Weight gain on dolutegravir/abacavir/FTC and darunavir/TDF/FTC was significantly greater than that for several integrase inhibitor-based regimens.

**Conclusions**—There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we observed greater gain among PLWH taking newer INSTIs (DTG, BIC) and DRV-based regimens.

### Keywords

HIV; weight; antiretroviral therapy; integrase strand transfer inhibitors; dolutegravir; bictegravir

### Introduction

In the early HIV era, people living with HIV (PLWH) experienced severe wasting[1], which can be juxtaposed with the current era, when some PLWH are gaining weight after initiating antiretroviral therapy (ART)[2–4]. Wasting and subsequent metabolic disturbances among untreated PLWH have been well-documented[1], but the mechanisms associated with weight gain among treated PLWH have not been fully characterized. A link between ART initiation and a return to health effect, in part characterized by increasing CD4 count and weight gain, has been postulated[2, 5–8]. However, in more recent years, the prevalence of PLWH with obesity has continued to increase[3, 9], which warrants further investigation.

Regimens containing integrase strand transfer inhibitors (INSTIs), a relatively recent class of ART drugs including raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), and bictegravir (BIC), demonstrated more rapid viral suppression compared to other ART classes, and are currently recommended as a component of initial HIV regimens[10–14]. Recent evidence has emerged documenting changes in body morphology in PLWH after initiating INSTIs[7, 15]. In particular, cases of atypical weight gain have occurred in some PLWH taking DTG[7, 16–19]. Excessive weight gain affects psychological[20] and social quality of life[21], as well as ART adherence[22], and can potentially lead to long-term adverse health outcomes[23–25] thus requiring monitoring of metabolic measures [25–27].

A potential association between INSTIs such as dolutegravir and weight gain has been suggested[7, 15–19, 28]. However, questions remain as prior studies have mainly been small[2, 16, 17], used historical rather than concurrent controls[17], did not include the most

recent INSTI drugs (e.g. BIC)[2, 9, 15, 28], did not account for other weight-impacting medications like antipsychotic medications[8, 9, 15, 17, 18], or were from trials that lack generalizability to the current diversity of PLWH in the United States[8, 17, 28]. In addition, many studies on weight change in PLWH on ART focused on ART class effects, thus were unable to compare individual agents[2, 9, 29]. Finally, many prior studies were not limited to PLWH initiating their first regimen, so they assessed outcomes after participants switched regimens, potentially allowing for carry-over effects from prior drugs[7, 9, 15, 28, 30]. To address these limitations, we conducted a large retrospective cohort study comparing weight gain in previously ART-naïve PLWH initiating various ART regimens in the current treatment era.

## Methods

### Overview and setting

The Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) is a dynamic cohort that includes >35,000 PLWH at eight academic clinical sites throughout the United States[31]. CNICS integrates verified clinical point-of-care data for its participants from outpatient and inpatient visits, including information on demographic characteristics, clinical and laboratory data and diagnoses, and medications.

### Study cohort

We assessed body weight change in ART-naïve PLWH initiating one of the 11 most common ART regimens containing three or more drugs between January 1, 2012 and November 30, 2019 (Supplement Table 1). Regimens assessed were efavirenz (EFV), rilpivirine (RPV), ritonavir-boosted atazanavir (ATV), ritonavir-boosted darunavir (DRV), raltegravir (RAL), cobicistat-boosted elvitegravir (EVG), and dolutegravir (DTG), all with tenofovir disoproxil fumarate (TDF) and emtricitabine. In addition, we assessed DTG, bictegravir (BIC), and cobicistat-boosted EVG with tenofovir alafenamide fumarate (TAF) and emtricitabine. We also included DTG with abacavir (ABC) and emtricitabine. Emtricitabine and lamivudine were not distinguished for these analyses. We required regimens to have a minimum of 90 PLWH initiating them to be sufficient for evaluation. No two-drug regimen met sufficient numbers (  $\geq 90$  PLWH) for inclusion. ART initiation date is hereinafter referred to as baseline and represents the start of follow-up. All PLWH were previously ART-naïve to eliminate impacts from prior regimens and maximize comparability among PLWH across regimens of interest. Follow-up for each PLWH ended when their initial ART regimen changed, ART was stopped, loss to follow-up or death, or the end of clinical data (varies somewhat by site, approximately 11/2019), whichever was earliest.

### Analysis

We conducted descriptive analyses of demographic and clinical characteristics of PLWH by regimen and assessed differences between regimens with t-tests for continuous variables and chi-squared tests for categorical variables. The main outcome, body weight change, was calculated as the difference in weight between a follow-up visit and baseline weight (measured at or immediately before baseline). We estimated body weight change by ART regimen using linear mixed models with exchangeable correlation matrices and robust

standard errors to account for within-subject correlations, random intercepts, and random slopes for time on ART[32]. We examined weight change in the immediate period (first 6 months) after ART initiation. All models were adjusted for age, sex, race/ethnicity, hepatitis C virus (HCV) (defined as positive detection of hepatitis C antibodies or RNA) and/or hepatitis B virus (HBV) coinfection (defined as positive test for hepatitis B surface antigen), nadir CD4 count (cells/mm<sup>3</sup>), diabetes mellitus (defined as a patient having a diabetes specific medication, a diabetes related medication with diabetes diagnosis, or a hemoglobin A1C value  $\geq 6.5$ ), smoking status, time-updated antipsychotic medication use (antipsychotic or antipsychotic plus antidepressant medication), clinical site, time on ART, and the interaction of time on ART and regimen.

Differences in body weight change between regimens were evaluated using Wald tests. As we were using linear mixed models, body weight change was evaluated using generalized additive models (GAM) to assess linearity and patterns of weight change over time to ensure parametric assumptions were met. Additional weight change sensitivity analyses incorporated extended follow-up time (excluded recently-approved regimens including TAF), time-updated CD4 count, stratification by baseline BMI ( $\geq 25$  kg/m<sup>2</sup> vs  $<25$  kg/m<sup>2</sup>) to assess the potential for a return to health effect, and exclusion of PLWH with a weight change in the top or bottom five percent of all observed weight changes to ensure the observed differences were not due to influential outliers.

## Results

We observed 3232 previously treatment-naïve PLWH in the CNICS cohort who initiated one of 11 ART regimens. Demographic and clinical characteristics of the study cohort by regimen are presented in Table 1. The EVG/TDF/FTC regimen had the most participants (24% of cohort), and the ATV/TDF/FTC (3%) and RAL/TDF/FTC (3%) regimens had the fewest. Overall average follow-up time on initial ART regimen was 1.9 years (Interquartile Range (IQR): 0.6–2.9). The mean age was 37 years and PLWH were predominantly male (84%). Overall, 35% of PLWH were white, 45% were black, and 13% were Hispanic. Hepatitis C coinfection was 9% on average, with a higher rate of coinfection among those on RAL/TDF/FTC (22%) and ATV/TDF/FTC (16%). Average nadir CD4 count among PLWH by regimen was between 295 and 432 cells/mm<sup>3</sup> (overall mean=381 cells/mm<sup>3</sup>). Average baseline weight was 79 kg (IQR: 67–89) and baseline BMI was 26 kg/m<sup>2</sup> (IQR: 22–28) for the entire cohort.

On average, the entire study cohort gained weight after ART initiation (Table 2). In the immediate period after ART initiation (N=3186), DRV/TDF/FTC was associated with a 3.7 kg (95% CI: 2.1–5.2) per 6 months greater weight gain, DTG/TAF/FTC was associated with a 4.4 kg (95% CI: 2.1–6.6) per 6 months greater gain, and BIC/TAF was associated with a 3.9 kg (95% CI: 2.2–5.5) per 6 months greater gain compared with EFV/TDF/FTC (Table 2). We assessed differences in weight gain directly between regimens. Weight gain on DTG/TAF/FTC and BIC/TAF/FTC were statistically significantly greater ( $p<0.05$ ) than EFV/TDF/FTC, RPV/TDF/FTC, EVG/TDF/FTC, and EVG/TAF/FTC regimens, but not statistically significantly greater than DTG/ABC/FTC ( $p=0.08$  vs. DTG/TAF/FTC;  $p=0.06$

vs. BIC/TAF/FTC) (Table 2). GAM plots restricted to the first 6 months after ART initiation suggest linear increases in weight during this period (Supplement Figure 1).

We conducted several sensitivity analyses of the extended period on the initial ART regimen. Among 2646 PLWH, average follow-up time was 2.1 years. PLWH taking DRV/TDF/FTC experienced the most weight gain, followed by those taking DTG/TDF/FTC and DTG/ABC/FTC, per 6 months compared to EFV/TDF/FTC (Supplement Table 2). The overall pattern of weight change by regimen did not differ when also adjusting for time-updated CD4 count. We stratified participants by baseline BMI (<25 kg/m<sup>2</sup> vs ≥25 kg/m<sup>2</sup>, Supplement Table 3), and weight change was similar between most strata of baseline BMI with a few small differences (e.g. more weight gain on ATV in lower vs. higher BMI group) (Supplement Table 4). PLWH with an observed weight change in the top or bottom five percent of all weight changes were evenly distributed across all regimens. The results after excluding these PLWH were generally similar to the analysis of the entire study cohort with greater weight gain among those on DRV/TDF/FTC and DTG-based regimens (Supplement Table 5).

## Discussion

Among PLWH initiating their first ART regimen in the current treatment era (2012–2019), we observed weight gain across all regimens. Weight gain was most rapid early after ART initiation. We found that in the immediate period (first 6 months) after ART initiation, weight gain was greatest for several recently approved regimens that, to-date, have limited data from real-world clinical settings. Specifically, we found more weight gain among PLWH initiating BIC/TAF/FTC and DTG/TAF/FTC compared to some other regimens. When we examined extended follow-up time, we found greater weight gain in INSTI- and DRV-based regimens compared to those on EFV/TDF/FTC. In particular, those taking DTG experienced more weight gain than PLWH who initiated EVG, a commonly used first-generation INSTI.

These observed differences in weight gain between regimens highlight differences between some new INSTIs and older regimens. In contrast to previous trials on drug efficacy, this study provides insight as to weight gain among PLWH in routine clinical care, [12, 33, 34]. We were also able to compare differences between TDF and TAF between regimens with the same core drug in PLWH in clinical care and found slightly greater weight gain in PLWH on the TAF-based regimens, as was noted in a large clinical trial in South Africa[28].

Return to health, characterized by an overall improvement in well-being, including increasing CD4 cell count and some weight gain, may occur following ART initiation in PLWH with poor health status who may have experienced wasting[2, 5]. An association between higher BMI and higher CD4 cell count among PLWH initiating their first ART regimen has been observed, but lacks causality and impact on other indicators of long-term health[35]. Return to health has been proposed as a possible mechanism to investigate weight gain after ART initiation, and superior virologic benefits of INSTIs could be a factor in a faster presentation of return to health. However, current recommendations for treatment advise beginning ART immediately, making this less salient [14]. In our study, the amount of weight gained on DTG and BIC regimens was greater than weight gained on some other

INSTIs, indicating that return to health does not explain the whole association between DTG and weight gain.

The strengths of this study include the comprehensive clinical data, antipsychotic medication use[36–38] and large, diverse sample size of PLWH in CNICS. CNICS also does frequent data updates and ongoing data quality control to ensure timely data. The strict inclusion criteria regarding regimen composition and duration of follow-up (i.e. ART-naïve at study start, follow-up ends when original regimen is switched or ended) eliminated possible carryover effects from other ART drugs or classes that other studies have not been able to avoid[7, 18].

This study also has limitations worth noting. There were variable lengths of follow-up time between PLWH on different regimens, particularly for newer regimens. Our primary analysis focused on the immediate (6-month) period after ART initiation to allow comparable follow-up time across regimens in the window when weight gain was most likely related to the drugs. We assessed each regimen individually, rather than by class, so there were some regimens with small sample sizes, such as ATV and RAL, limiting power and our ability to compare these regimens with others. As an observational study, unmeasured confounding is a limitation. Finally, while CNICS is a large, diverse cohort, our study population was mostly male, and recent findings suggest that women may be more likely to experience treatment-related weight gain[39].

## Conclusion

This study found more weight gain among previously ART-naïve PLWH on newer INSTIs (DTG and BIC) and DRV-based regimens in the current ART treatment era, although weight gain appeared to plateau over time. Longer-term observation of PLWH taking INSTIs is warranted.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements:

We would like to acknowledge all CNICS study participants and personnel for their contributions to this work. We would also like to acknowledge the contributions to this paper made by Benigno Rodriguez and honor his memory and his many contributions to improving the health of PLWH.

**Sources of financial support:** Funding was provided by ViiV Healthcare. ViiV had no influence on data collection, analysis, or decision to publish. ViiV co-authors provided input on interpretation and suggestions for critical revisions of the draft but all final decisions on content were made by SR, JAD, and HC. CNICS is funded by the National Institutes of Health who had no role in study design or the manuscript. The corresponding author had access to data and bears responsibility for the manuscript. Additional support came from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health [CNICS R24 AI067039, UW CFAR NIAID Grant P30 AI027757; UNC CFAR grant P30 AI50410, JHU CFAR grant P30 AI094189, and UAB CFAR grant P30 AI027767] and the National Institute of Drug Abuse R01DA047045.

## References

1. Grunfeld C and Feingold KR, Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. *N Engl J Med*, 1992 327(5): p. 329–37. [PubMed: 1620172]
2. Lakey W, et al., Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. *AIDS Res Hum Retroviruses*, 2013 29(3): p. 435–40. [PubMed: 23072344]
3. Koethe JR, et al., Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. *AIDS Res Hum Retroviruses*, 2016 32(1): p. 50–8. [PubMed: 26352511]
4. Tate T, et al., HIV infection and obesity: where did all the wasting go? *Antivir Ther*, 2012 17(7): p. 1281–9. [PubMed: 22951353]
5. Grant PM, et al., Long-term body composition changes in antiretroviral-treated HIV-infected individuals. *AIDS*, 2016 30(18): p. 2805–2813. [PubMed: 27662545]
6. Lake JE, et al., Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection. *Clin Infect Dis*, 2017 64(10): p. 1422–1429. [PubMed: 28329372]
7. Norwood J, et al., Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. *J Acquir Immune Defic Syndr*, 2017 76(5): p. 527–531. [PubMed: 28825943]
8. Yuh B, et al., Weight change after antiretroviral therapy and mortality. *Clin Infect Dis*, 2015 60(12): p. 1852–9. [PubMed: 25761868]
9. Bakal DR, et al., Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors. *J Antimicrob Chemother*, 2018 73(8): p. 2177–2185. [PubMed: 29722811]
10. Nance RM, et al., HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study. *Ann Intern Med*, 2018 169(6): p. 376–384. [PubMed: 30140916]
11. Hicks C and Gulick RM, Raltegravir: the first HIV type 1 integrase inhibitor. *Clin Infect Dis*, 2009 48(7): p. 931–9. [PubMed: 19231980]
12. Sax PE, et al., Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet*, 2017 390(10107): p. 2073–2082. [PubMed: 28867499]
13. Boffito M and Venter F, The triumph of HIV treatment: another new antiretroviral. *Lancet*, 2017 390(10107): p. 2019–2021. [PubMed: 28867498]
14. Saag MS, et al., Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. *JAMA*, 2018 320(4): p. 379–396. [PubMed: 30043070]
15. Bhagwat P, et al., Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race. *Open Forum Infect Dis*, 2018 5(11): p. ofy201. [PubMed: 30465010]
16. Menard A, et al., Dolutegravir and weight gain: an unexpected bothering side effect? *AIDS*, 2017 31(10): p. 1499–1500. [PubMed: 28574967]
17. Rizzardo S, et al., Dolutegravir monotherapy and body weight gain in antiretroviral naive patients. *AIDS*, 2019 33(10): p. 1673–1674. [PubMed: 31305333]
18. Bourgi K, et al., Greater Weight Gain in Treatment Naive Persons Starting Dolutegravir-Based Antiretroviral Therapy. *Clin Infect Dis*, 2019.
19. Wood BR, Do Integrase Inhibitors Cause Weight Gain? *Clin Infect Dis*, 2020 70(7): p. 1275–1277. [PubMed: 31100105]
20. Crane HM, et al., Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy. *HIV Med*, 2008 9(9): p. 780–6. [PubMed: 18754804]

21. Mutimura E, Stewart A, and Crowther NJ, Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. *AIDS Res Ther*, 2007 4: p. 19. [PubMed: 17877798]
22. Plankey M, et al., Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study. *AIDS Behav*, 2009 13(1): p. 53–9. [PubMed: 18688706]
23. Colditz GA, et al., Weight gain as a risk factor for clinical diabetes mellitus in women. *Ann Intern Med*, 1995 122(7): p. 481–6. [PubMed: 7872581]
24. Chan JM, et al., Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes Care*, 1994 17(9): p. 961–9. [PubMed: 7988316]
25. Kumar S and Samaras K, The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. *Front Endocrinol (Lausanne)*, 2018 9: p. 705. [PubMed: 30542325]
26. Koethe JR, et al., The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. *AIDS*, 2016 30(1): p. 83–91. [PubMed: 26418084]
27. Nansseu JR, et al., Incidence and Risk Factors for Prediabetes and Diabetes Mellitus Among HIV-infected Adults on Antiretroviral Therapy: A Systematic Review and Meta-analysis. *Epidemiology*, 2018 29(3): p. 431–441. [PubMed: 29394189]
28. Venter WDF, et al., Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. *N Engl J Med*, 2019 381(9): p. 803–815. [PubMed: 31339677]
29. Debroy P, et al., Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot. *J Antimicrob Chemother*, 2019 74(4): p. 1028–1034. [PubMed: 30668716]
30. Lake JE, et al., Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. *Clin Infect Dis*, 2020.
31. Kitahata MM, et al., Cohort profile: The Centers for AIDS Research Network of Integrated Clinical Systems. *International Journal of Epidemiology*, 2008 37(5): p. 948–955. [PubMed: 18263650]
32. Diggle P, et al., *Analysis of longitudinal data*. Second edition / ed. 2002, Oxford: Oxford University Press xv, 379 pages.
33. Raffi F, et al., Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. *Lancet*, 2013 381(9868): p. 735–43. [PubMed: 23306000]
34. Llibre JM, et al., Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. *PLoS One*, 2016 11(7): p. e0159286. [PubMed: 27391807]
35. Koethe JR, et al., Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. *J Acquir Immune Defic Syndr*, 2016 73(2): p. 197–204. [PubMed: 27116044]
36. Stoskopf CH, Kim YK, and Glover SH, Dual diagnosis: HIV and mental illness, a population-based study. *Community Ment Health J*, 2001 37(6): p. 469–79. [PubMed: 11504140]
37. Huhn M, et al., Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet*, 2019.
38. McIntyre RS, McCann SM, and Kennedy SH, Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. *Can J Psychiatry*, 2001 46(3): p. 273–81. [PubMed: 11320682]
39. Mascolini M, More Weight, Trunk Fat, Metabolic Syndrome With DTG+TAF/FTC in South African Trial, in *AIDS 2020: 23rd International AIDS Conference Virtual*. 2020: Virtual.



Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 1.**

Demographic and clinical characteristics of people living with HIV from CNICS sites across the United States who initiated their first antiretroviral therapy regimen between 2012–2019.

N (%) or Mean (SD) <sup>a</sup>	Everyone	EFV	RPV	ATV	DRV	RAL	EVG/TDF	EVG/TAF	DTG/TDF	DTG/TAF	DTG/ABC	BIC
N	3232 (100)	427 (13)	347 (11)	97 (3)	263 (8)	99 (3)	787 (24)	289 (9)	237 (7)	127 (4)	389 (12)	170 (5)
Age (years)	37 (12)	37 (11)	35 (11)	35 (11)	38 (11)	43 (12)	35 (11)	35 (12)	39 (13)	39 (13)	38 (13)	35 (11)
Female (N (%))	505 (16)	34 (8)	61 (18)	32 (33)	47 (18)	22 (22)	103 (13)	35 (12)	44 (19)	22 (17)	80 (21)	25 (15)
Race/ethnicity												
White (N (%))	1136 (35)	185 (43)	102 (29)	41 (42)	99 (38)	56 (57)	273 (35)	87 (30)	100 (42)	43 (34)	108 (28)	42 (25)
Black (N (%))	1463 (45)	149 (35)	165 (48)	46 (47)	103 (39)	27 (27)	374 (48)	136 (47)	87 (37)	60 (47)	211 (54)	105 (62)
Hispanic (N (%))	402 (13)	67 (16)	52 (15)	6 (6)	44 (17)	9 (9)	86 (11)	43 (15)	29 (12)	13 (10)	43 (11)	10 (6)
Other (N (%))	231 (7)	26 (6)	28 (8)	4 (4)	17 (6)	7 (7)	54 (7)	23 (8)	21 (9)	11 (9)	27 (7)	13 (8)
HCV (N (%))	298 (9)	32 (7)	25 (7)	16 (16)	33 (13)	22 (22)	51 (6)	33 (11)	26 (11)	14 (11)	30 (8)	16 (9)
HBV (N (%))	84 (3)	5 (1)	10 (3)	3 (3)	7 (3)	3 (3)	29 (4)	7 (2)	10 (4)	3 (2)	3 (1)	4 (2)
Nadir CD4 (cells/mm <sup>3</sup> )	381 (249)	400 (245)	432 (201)	373 (220)	295 (232)	375 (252)	378 (253)	425 (273)	325 (228)	372 (272)	388 (255)	379 (270)
Smoker (N (%))	633 (20)	79 (19)	67 (19)	28 (29)	63 (24)	23 (23)	139 (18)	52 (18)	59 (25)	41 (32)	53 (14)	29 (17)
Diabetes (N (%))	152 (5)	19 (4)	16 (5)	2 (2)	11 (4)	5 (5)	26 (3)	11 (4)	19 (8)	5 (4)	30 (8)	8 (5)
Baseline weight (kg)	79 (19)	80 (17)	81 (19)	80 (18)	77 (17)	80 (18)	79 (18)	79 (21)	75 (16)	80 (18)	82 (21)	80 (20)
Baseline BMI (kg/m <sup>2</sup> )	26 (6)	26 (5)	27 (6)	26 (6)	25 (5)	26 (5)	26 (6)	26 (7)	25 (5)	26 (6)	27 (7)	26 (6)
Years on regimen (years)	1.9 (1.6)	2.2 (1.9)	2.6 (2.0)	1.8 (1.8)	1.9 (1.6)	2.2 (1.8)	2.2 (1.6)	1.6 (1.0)	1.3 (1.2)	1.1 (0.8)	2.1 (1.4)	0.5 (0.3)

Definitions: EFV (Efavirenz®), RPV (Educan®), Complera®, Odefsey®, ATV (Aazanavir®), DRV (Prezista®), Prezcoibix®, RAL (Isentress®), Isentress HD®, EVG (Vitekta®, Stribild®, Genvoya®), DTG (Tivicay®, Triumeq®), BIC (Biktarvy®), ABC (abacavir), TDF (tenofovir disoproxil fumarate), TAF (tenofovir alafenamide fumarate)

Abbreviations: HCV: hepatitis C virus; HBV: hepatitis B virus; BMI: body mass index; CNICS: Centers for AIDS Research Network of Integrated Clinical Systems

<sup>a</sup> All tests for differences between regimens tested significant at p<0.05, except HBV (p=0.13)

**Table 2.**

Weight change ( kg/6 months) in the immediate period (first 6-months) among people living with HIV from CNICS sites across the United States who initiated their first antiretroviral therapy regimen between 2012–2019 (n=3186) in adjusted<sup>a</sup> analyses (linear mixed models)

	kg/6 months	95% CI		P-value
Time on regimen (EFV reference)	0.71	-0.12	1.53	0.09
Reg type x Time on regimen				
1: RPV	-0.36	-1.62	0.90	0.58
2: ATV	2.15	-0.01	4.30	0.051
3: DRV	3.68	2.13	5.22	<0.001
4: RAL	2.06	0.11	4.01	0.04
5: EVG/TDF	1.81	0.72	2.90	<0.01
6: EVG/TAF	1.88	0.61	3.16	<0.01
7: DTG/TDF	2.61	1.29	3.92	<0.001
8: DTG/TAF <sup>b</sup>	4.37	2.10	6.64	<0.001
9: DTG/ABC	2.28	1.06	3.49	<0.001
10: BIC <sup>c</sup>	3.86	2.24	5.48	<0.001

Abbreviations: CNICS: Centers for AIDS Research Network of Integrated Clinical Systems, EFV: efavirenz, RPV: rilpivirine, ATV: atazanavir, DRV: darunavir, RAL: raltegravir, EVG: elvitegravir, DTG: dolutegravir, BIC: bictegravir, TDF: tenofovir disoproxil fumarate, TAF: tenofovir alafenamide fumarate, ABC: abacavir

<sup>a</sup>Model adjusted for time on regimen, regimen, age, sex, race/ethnicity, Hepatitis C, Hepatitis B, nadir CD4, smoking, diabetes, site, and antipsychotic medication use (time-updated)

<sup>b</sup>DTG/TAF tested different using a Wald test vs EFV, RPV, EVG/TDF, EVG/TAF; DTG/ABC: p=0.08

<sup>c</sup>BIC tested different using a Wald test vs EFV, RPV, EVG/TDF, EVG/TAF; DTG/ABC: p=0.06